Zelnorm

Zelnorm was a brand of sold by Novartis from 2002 to 2007, and later by Alfasigma from 2019 to 2022. The drug was first withdrawn from markets and discontinued in 2007 due to the Food and Drug Administration's concerns about it causing possible adverse cardiovascular effects. It would later be brought back in 2019, but was voluntarily discontinued by its new manufacturer in 2022, citing a business decision rather than any concerns regarding the safety or efficacy of the drug.
__NOTOC__
==2002–2007==
Zelnorm was withdrawn and discontinued in 2007 following concerns about dangerous side effects.
==2019–2022==
In 2019, the Zelnorm brand was revived by Alfasigma as a treatment for IBS-C in female patients under 65 years old.
In 2022, it was discontinued by its manufacturer, which cited a business decision rather than any concerns regarding the safety or efficacy of the drug.
==External links==
Category:Novartis
Category:Alfasigma
Category:Drugs
Category:Medicine
Category:Pharmaceutical
Category:Prescription medicines
Category:Revived products
Category:Defunct
Category:Discontinued
Category:Defunct brands
Category:Discontinued drug brands
Category:Medicines in the United States
Category:Medicines in Australia
Category:Medicines in Canada
Category:United States
Category:2000s
Category:2002